Heterogeneity of Ventral Tegmental Area Neurons and Opioid Reward

腹侧被盖区神经元的异质性和阿片类药物奖励

基本信息

项目摘要

DESCRIPTION (provided by applicant): Approximately 2 million people are dependent on or abuse opioids in the USA each year (www.dhhs.gov), and NIDA reports that illicit opiate use is on the rise. Accumulating evidence indicates that alcohol consumption and rewarding events cause the release of endogenous opioids in the brain, therefore utilizing the same mu opioid receptors (MORs) and brain circuits involved in opiate addiction. In spite of the magnitude of this problem, we only partially understand how MOR activation causes reward and leads to addiction. Therefore overall objective of this proposal is to investigate the circuits that contribute to opioid reward. MORs in the ventral tegmental area (VTA) are required for morphine reward (Olmstead and Franklin, 1997b; Zhang et al., 2009). VTA neurons release dopamine in the ventral striatum, and it is commonly thought that dopamine released in the ventral striatum causes opioid reward. Yet, lesions of the ventral striatum do not block morphine reward (Olmstead and Franklin, 1996, 1997a; White et al., 2005). Instead, lesions of the medial prefrontal cortex (mPFC) do block morphine reward (Tzschentke and Schmidt, 1999). Therefore the proposed experiments focus on MOR control of mPFC-projecting VTA neurons. Detailed anatomy of this projection will be studied, in particular to test whether the newly discovered VTA glutamate neurons project to the mPFC. Because morphine reward is dopamine-independent in opiate na¿ve animals (Bechara et al., 1992; Nader and van der Kooy, 1997), it is critical to determine the effects of MOR activation on both the non-dopamine and dopamine VTA neurons that project to the mPFC. Cortical-projecting neurons will be retrogradely labeled so that they can be identified during brain slice recordings, and pre- and postsynaptic MOR agonist effects will be measured electrophysiologically in these labeled neurons. Following recordings, the neurotransmitter content of the recorded neurons will be directly identified as dopamine, glutamate, or GABA using immunocytochemistry or in situ hybridization. Since electrical stimulation of the mPFC is rewarding (Corbett et al., 1982; Duvauchelle and Ettenberg, 1991), it is hypothesized that MOR activation will excite mPFC-projecting dopamine and glutamate neurons, and inhibit GABA neurons. By improving our understanding of the circuitry involved in opioid reward, this work will enable more effective therapeutic development for disorders that involve VTA and mPFC signaling, including addiction, alcoholism, impulsivity disorders and attention deficit hyperactivity disorder.
描述(由适用提供):每年约有200万人依赖于美国的阿片类药物(www.dhhs.gov),而NIDA报告说,非法优化使用的使用正在上升。积累的证据表明,饮酒和奖励事件会导致大脑中内源性阿片类药物的释放,因此利用相同的MU阿片受体(MORS)和涉及优化成瘾的脑回路。尽管有这个问题的幅度,但我们只部分理解MOR激活如何引起奖励并导致成瘾。因此,该提案的总体目标是调查有助于阿片类药物奖励的电路。吗啡奖励需要腹侧对接区域(VTA)(VTA)(Olmstead和Franklin,1997b; Zhang等,2009)。 VTA神经元在腹侧纹状体中释放多巴胺,通常认为在腹侧纹状体中释放的多巴胺会导致OOid奖励。然而,腹纹状体的病变不会阻止吗啡奖励(Olmstead和Franklin,1996,1997a; White等,2005)。取而代之的是,中位前额叶皮层(MPFC)的病变会阻止吗啡奖励(Tzschentke and Schmidt,1999)。因此,提出的实验侧重于对MPFC投射VTA神经元的MOR控制。该投影的详细解剖结构将进行研究,特别是用于测试新发现的VTA谷氨酸神经元是否向MPFC进行。由于吗啡奖励是多巴胺在阿片类动物中与多巴胺无关的(Bechara等,1992; Nader and van der Kooy,1997),因此确定MOR激活对非多巴胺和多巴胺VTA神经元的影响至关重要。皮质预测的神经元将逆行标记,以便可以在脑切片记录中鉴定出它们,并且在这些标记的神经元中将通过电生理测量突触前和突触后的MONIST效应。以下记录,使用免疫细胞化学或原位杂交直接将记录神经元的神经递质含量直接鉴定为多巴胺,谷氨酸或GABA。由于MPFC的电刺激是奖励的(Corbett等,1982; Duvauchelle和Ettenberg,1991),因此假设MOR激活会激发MPFC-PROTORATION多巴胺和谷氨酸神经元,并抑制GABA神经元。通过提高我们对阿片类药物奖励所涉及的电路的理解,这项工作将使涉及VTA和MPFC信号传导的疾病的更有效的治疗性发育,包括加法,酒精中毒,冲动性疾病和注意力缺陷多功能障碍。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Elyssa Margolis其他文献

Elyssa Margolis的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Elyssa Margolis', 18)}}的其他基金

A highly opioid responsive VTA projection to the dorsal endopiriform nucleus.
高度阿片类药物反应的 VTA 投射到背内核状核。
  • 批准号:
    10739039
  • 财政年份:
    2023
  • 资助金额:
    $ 35.42万
  • 项目类别:
Resolving differences between clinical opioids at single neurons
解决临床阿片类药物在单个神经元上的差异
  • 批准号:
    10355433
  • 财政年份:
    2021
  • 资助金额:
    $ 35.42万
  • 项目类别:
Understanding endogenous opioid drive of alcohol consumption
了解饮酒的内源性阿片类药物驱动力
  • 批准号:
    10190738
  • 财政年份:
    2018
  • 资助金额:
    $ 35.42万
  • 项目类别:
Understanding endogenous opioid drive of alcohol consumption
了解饮酒的内源性阿片类药物驱动力
  • 批准号:
    10436820
  • 财政年份:
    2018
  • 资助金额:
    $ 35.42万
  • 项目类别:
The role of the VTA-lateral habenula circuit in opioid mediated behaviors
VTA-外侧缰核回路在阿片类药物介导的行为中的作用
  • 批准号:
    10198878
  • 财政年份:
    2017
  • 资助金额:
    $ 35.42万
  • 项目类别:
Heterogeneity of Ventral Tegmental Area Neurons and Opioid Reward
腹侧被盖区神经元的异质性和阿片类药物奖励
  • 批准号:
    8681802
  • 财政年份:
    2013
  • 资助金额:
    $ 35.42万
  • 项目类别:
Heterogeneity of Ventral Tegmental Area Neurons and Opioid Reward
腹侧被盖区神经元的异质性和阿片类药物奖励
  • 批准号:
    8026051
  • 财政年份:
    2011
  • 资助金额:
    $ 35.42万
  • 项目类别:
Heterogeneity of Ventral Tegmental Area Neurons and Opioid Reward
腹侧被盖区神经元的异质性和阿片类药物奖励
  • 批准号:
    8209062
  • 财政年份:
    2011
  • 资助金额:
    $ 35.42万
  • 项目类别:
Heterogeneity of Ventral Tegmental Area Neurons and Opioid Reward
腹侧被盖区神经元的异质性和阿片类药物奖励
  • 批准号:
    8409810
  • 财政年份:
    2011
  • 资助金额:
    $ 35.42万
  • 项目类别:

相似国自然基金

内源激动剂ArA靶向TMEM175蛋白缓解帕金森病症的分子机制研究
  • 批准号:
    32300565
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
Adrb2激动剂在改善呼吸机相关性膈肌功能障碍中的作用与机制研究
  • 批准号:
    82372196
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
新型IL2Rβγ激动剂逐级控释联合放疗对抗三阴性乳腺癌的作用及机制研究
  • 批准号:
    82303819
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
基于OSMAC-GNPS分析策略的蚂蚱内生真菌Aspergillus sp.中新颖泛PPAR激动剂的发现及治疗NASH研究
  • 批准号:
    82304340
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
探究FSP1激动剂在治疗肾缺血再灌注损伤中的分子机理与应用
  • 批准号:
    82304600
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Multifunctional Nanoparticle Platform to Prevent Alcohol-Associated HCC Development
多功能纳米颗粒平台可预防酒精相关的 HCC 发展
  • 批准号:
    10736984
  • 财政年份:
    2023
  • 资助金额:
    $ 35.42万
  • 项目类别:
Goblet cells and intestinal immune response in alcohol-associated liver disease
酒精相关性肝病中的杯状细胞和肠道免疫反应
  • 批准号:
    10446819
  • 财政年份:
    2022
  • 资助金额:
    $ 35.42万
  • 项目类别:
Goblet cells and intestinal immune response in alcohol-associated liver disease
酒精相关性肝病中的杯状细胞和肠道免疫反应
  • 批准号:
    10681329
  • 财政年份:
    2022
  • 资助金额:
    $ 35.42万
  • 项目类别:
GPR88 Agonist for Alcoholism Treatment
用于治疗酒精中毒的 GPR88 激动剂
  • 批准号:
    10459403
  • 财政年份:
    2018
  • 资助金额:
    $ 35.42万
  • 项目类别:
GPR88 Agonist for Alcoholism Treatment
用于治疗酒精中毒的 GPR88 激动剂
  • 批准号:
    10226303
  • 财政年份:
    2018
  • 资助金额:
    $ 35.42万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了